Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · HALEOS LABS LIMITED · 9 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
HALEOS LABS LIMITED
NSE: HALEOSLABS · BSE: 540679
NSE: HALEOSLABS · BSE: 540679
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
HALEOS LABS LIMITED
StateQ1 FY27 filed
Last close · 8 Oct 2026₹1,574.00
Market cap₹0.5k cr
TTM P/E · P/B · EV/EBITDA30.1 · 2.07 · 13.3
HALEOS LABS LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 350 | 316 | 306 | 345 | 334 |
| EBITDA (ex other income) | 47 | 31 | 31 | 45 | 45 |
| margin % | 13.4 | 9.9 | 10.2 | 13.1 | 13.4 |
| Owners' profit | 25 | 11 | 9 | 20 | 17 |
| EPS, as reported (₹) | 83.68 | 37.92 | 30.08 | 66.51 | 57.26 |
| ROE % · ROCE % | 15.3 · 17.6 | 6.0 · 8.9 | 3.3 · 8.1 | 8.8 · 14.1 | 7.8 · 10.6 |
| Debt / equity (x) | 0.47 | 0.52 | 0.50 | 0.40 | 0.47 |
| Cash from operations | (11) | 15 | 24 | 34 | 37 |
| Capex | (51) | (49) | (21) | (15) | (58) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · HALEOS LABS LIMITED · 9 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 78 | 85 | 89 | 83 | 81 | 95 | 75 | 73 |
| Profit before tax | 5 | 7 | 4 | 7 | 8 | 9 | 1 | 3 |
| Net profit | 3 | 5 | 3 | 4 | 6 | 7 | 0 | 2 |
| EPS (₹) | 15.46 | 18.08 | 9.83 | 13.75 | 20.19 | 21.89 | 1.44 | 8.75 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,22,229 | 34.9 | 5.03 | 22.6 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,48,067 | 84.9 | 14.80 | 64.0 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,56,270 | 73.8 | 8.89 | 38.8 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,10,978 | 24.8 | 3.75 | 14.4 | 17.3 | 18.0 | 12.4 | 25.2 |
| LAURUS LABS LIMITED | 1,07,937 | 98.6 | 19.87 | 60.1 | 16.4 | 17.2 | 7.2 | 32.0 |
| CIPLA LTD | 1,05,570 | 31.3 | 3.06 | 16.1 | 11.2 | 14.7 | 8.0 | 19.7 |
| DR. REDDY S LABORATORIES | 98,530 | 30.5 | 2.58 | 13.2 | 10.9 | 13.0 | 12.1 | 15.0 |
| MANKIND PHARMA LIMITED | 98,294 | 48.1 | 5.94 | 27.1 | 11.7 | 10.8 | — | 27.3 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 30.1 | 31.2 | 77 of 158 | 52% |
| P/B | 2.1 | 3.1 | 54 of 163 | 67% |
| ROCE | 8.4 | 10.8 | 109 of 183 | 41% |
| ROE | 7.8 | 9.8 | 97 of 166 | 42% |
| Debt / Equity | 0.5 | 0.2 | 135 of 166 | 19% |
| EBITDA margin | 13.1 | 17.5 | 101 of 165 | 39% |
| Revenue growth | (11.6) | 16.3 | 136 of 161 | 16% |
| Profit growth | (58.0) | 30.9 | 137 of 158 | 13% |
| Market cap | 476 | 857 | 98 of 181 | 46% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · HALEOS LABS LIMITED · 9 October 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 1 Oct 2026 · Haleos Labs 20th AGM: All 8 resolutions passed, FY26 dividend declared | board shareholder meetings | low | — | — |
| 30 Sept 2026 · 20th AGM held; 15% dividend declared, key resolutions passed | board shareholder meetings | low | — | — |
| 21 Sept 2026 · Trading Window Closed from Oct 1 for Q2 Results | compliance | minimal | — | — |
| 18 Sept 2026 · Haleos Labs subsidiary clears USFDA inspection with zero observations | business updates | high | — | — |
| 9 Sept 2026 · Weblink for 20th AGM Notice and Annual Report sent to physical shareholders | compliance | minimal | — | — |
| 8 Sept 2026 · Haleos Labs 20th AGM on Sep 30, Dividend Rs 1.50 per share proposed | compliance | minimal | — | — |
| 8 Sept 2026 · Notice of 20th AGM on 30 Sep 2026; dividend of Rs 1.50 per share | board shareholder meetings | low | — | — |
| 8 Sept 2026 · FY26 Annual Report filed; 20th AGM on Sep 30 with Rs 1.50 dividend | board shareholder meetings | medium | — | — |
| 5 Sept 2026 · Record date set as September 23, 2026 for FY26 dividend and 20th AGM | corporate actions | high | — | — |
| 5 Sept 2026 · Haleos Labs schedules 20th AGM on September 30, 2026 via video conferencing | board shareholder meetings | low | — | — |
Source: exchange announcements; reaction = close-to-close from the filing's session.
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in